The diagnosis and treatment of attention-deficit hyperactivity disorder (ADHD) in older adults
2023 (English)In: Expert Review of Neurotherapeutics, ISSN 1473-7175, E-ISSN 1744-8360, Vol. 23, no 10, p. 883-893Article, review/survey (Refereed) Published
Abstract [en]
INTRODUCTION: There is a striking knowledge gap on ADHD in older adults, and the diagnosis as well as treatment for ADHD in this age group.
AREAS COVERED: The authors first review the literature on the prevalence, functional impairment, and health comorbidities of ADHD across the lifespan. Next, they address the diagnostic criteria for ADHD in adults according to the DSM/ICD, available screening/diagnostic tools, differential diagnosis, and the validity of diagnostic criteria for ADHD in older adults. Finally, the authors focus on empirical evidence on the prevalence rates, medication response, and safety of pharmacological treatment of ADHD in older adults, and national and international clinical guidelines on the treatment of ADHD in this age group. E
XPERT OPINION: It is expected that future editions of the DSM and ICD will provide specifiers to the standard ADHD criteria, to better inform the diagnosis of ADHD in older adults. It is also expected that the increasing number of epidemiological studies will provide rigorous estimates on the prevalence, incidence, and burden of ADHD in older adults. One may expect an increasing number of RCTs assessing the efficacy/effectiveness and tolerability/safety of pharmacological as well as non-pharmacological interventions which will inform future guidelines on ADHD in older adults.
Place, publisher, year, edition, pages
Expert Reviews Ltd. , 2023. Vol. 23, no 10, p. 883-893
Keywords [en]
Attention-deficit hyperactivity disorder (ADHD), comorbidity, diagnosis, functional impairment, older adults, prevalence, treatment, treatment recommendations
National Category
Psychiatry
Identifiers
URN: urn:nbn:se:oru:diva-108379DOI: 10.1080/14737175.2023.2250913ISI: 001075570900003PubMedID: 37725058Scopus ID: 2-s2.0-85171670202OAI: oai:DiVA.org:oru-108379DiVA, id: diva2:1798693
Funder
EU, Horizon 2020, 754285 965381Swedish Research Council, 2018-02599 2022-01119The Swedish Brain Foundation, FO2021-0115 FO2022-0327
Note
M Dobrosavljevic acknowledges funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No [754285]. H Larsson acknowledges financial support from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 965381, the Swedish Research Council [2018-02599; 2022-01119] and the Swedish Brain Foundation [FO2021-0115; FO2022-0327]. S Cortese acknowledges research support through grants from the National Institute for Health and Care Research (NIHR) [NIHR203684; NIHR203035; NIHR130077; NIHR128472; RP-PG-0618-20003] and the European Research Agency [101095568-HORIZON- HLTH-2022-DISEASE-07-03].
2023-09-202023-09-202023-12-08Bibliographically approved